

Please try another search
Corvus Pharmaceuticals, Inc. (CRVS) reported Q3 EPS of $0.32, $0.47 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .
After-Hours Stock Movers: 9 Meters Biopharma Inc (NASDAQ:NMTR) 42% HIGHER; announced today positive final results from the Phase 2 study of vurolenatide and the outcome from its End-of-Phase 2 meeting...
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) reported Q2 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .
Concerns over the resurgence of COVID-19 cases, rising Treasury yields, and high inflation made September the worst month for the major stock market indexes since the onset of the pandemic. However,...
The biotech industry continues to play a crucial role in developing solutions to treat critical ailments. In addition, the demand for biotech solutions is also high across other sectors such as food...
Corvus Pharmaceuticals (NASDAQ:CRVS) has been making headway on several developments in the immuno-oncology therapies space, which sent its shares soaring to their 52-week high of $9.54 on September...
Investing.com – U.S. stocks were lower after the close on Friday, as losses in the Basic Materials, Utilities and Technology sectors led shares lower. At the close in NYSE, the Dow Jones Industrial...
Rapid adoption of advanced technologies, coupled with continued investments in developing breakthrough drugs, makes the prospects bright for the biotech industry. Moreover, the success of biotech...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review